Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 799 across all filing types
Latest filing 2017-01-16 Regulatory Filings
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
European Commission amends Marketing Authorisation for RUCONEST® to include self-administration
Regulatory Filings Classification · 95% confidence The document is a press release dated January 16, 2017, announcing that the European Commission has amended the Marketing Authorisation for RUCONEST® to include self-administration. It details the regulatory decision, the implications for patients, and includes commentary from the COO and background information on the disease (HAE) and the product. This type of announcement, focusing on a specific regulatory or commercial event (like a label change or approval update) that is not a full financial report (10-K, IR) or a general earnings release (ER), fits best under the category of a general regulatory announcement or news release. Since it is a specific, material announcement that doesn't fit the other specific categories (like DIV, CAP, MANG, DIRS), the most appropriate classification is Regulatory Filings (RNS), which serves as a broad category for significant, non-standard corporate news releases.
2017-01-16 English
Pharming announces completion of acquisition of all North American commercialisation rights for RUCONEST® from Valeant
Capital/Financing Update Classification · 95% confidence The document is a press release titled "Pharming announces completion of acquisition of all North American commercialisation rights for RUCONEST® from Valeant." It details a significant corporate transaction, including the deal structure (upfront fee, milestones), funding mechanisms (new equity, debt, convertible bonds), and the immediate operational impact. This type of announcement, focusing on corporate finance, M&A activity, and capital structure changes, strongly aligns with the Capital/Financing Update (CAP) category, especially given the detailed breakdown of the €104 million funding package. While it involves an acquisition (TAR), the primary focus and immediate news hook are the financing and the resulting capital structure change to support the newly acquired asset. Since the document is a detailed announcement of a transaction and its funding, CAP is the most appropriate fit over TAR (which usually implies the proposal/bid stage) or RNS (which is a general fallback). The length (over 20,000 characters) confirms it is the primary document, not just an announcement of a report.
2016-12-08 English
Pharming announces completion of financing for RUCONEST® North American Rights Acquisition
Capital/Financing Update Classification · 99% confidence The document is a press release announcing the completion of a financing round totaling €104 million, which includes new debt, convertible bonds, and a rights issue. The purpose of this financing is explicitly stated as paying the upfront amount for the acquisition of North American commercialization rights for RUCONEST® from Valeant. The text details the structure of the financing (debt facility, convertible bonds, rights issue) and summarizes the net proceeds and their intended use. This content directly relates to fundraising, capital structure changes, and financing activities, making it a Capital/Financing Update.
2016-12-07 English
Pharming Launches Rights Issue to raise €12.1 million as part of RUCONEST® North American Rights Acquisition Financing
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces the launch of a 'Rights Issue' to raise capital (€12.1 million) to finance an acquisition. It details the terms (1 for 7 issue price, discount), provides a timetable, and mentions that a 'Prospectus for the Rights Issue has been published'. A Rights Issue is a specific type of capital/financing activity. This directly aligns with the definition for Capital/Financing Update (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or just an announcement of a report (RPA), as the core content is the financing terms themselves.
2016-11-22 English
Pharming Announces Financing Plans for Closing of RUCONEST® North American Rights Acquisition
Capital/Financing Update Classification · 98% confidence The document is an announcement by Pharming Group N.V. detailing its financing plans, which include a Rights Issue, new debt facilities, and convertible bonds, all aimed at completing the acquisition of RUCONEST® North American rights. The text explicitly mentions raising capital through a 'Rights Issue' and securing debt/convertible bonds. This activity directly relates to changes in the company's capital structure and fundraising efforts. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not a full 10-K, an earnings release (ER), or a proxy statement (PSI), but a specific announcement about raising funds.
2016-11-21 English
Pharming Announces the Presentation of the Results of the RUCONEST® Phase II Study for Prophylaxis of Hereditary Angioedema Attacks
Regulatory Filings Classification · 95% confidence The document is an announcement from Pharming Group N.V. dated November 14, 2016, stating that the results of a clinical study (RUCONEST® Phase II) were presented at a medical meeting (ACAAI 2016). It provides context about the drug (RUCONEST®), the disease (HAE), and includes boilerplate information about the company and forward-looking statements. This is a press release announcing the presentation of study results, not the full financial report (10-K or IR), a formal earnings release (ER), or a transcript (CT). Since it is an announcement regarding clinical/product data presentation, it fits best under the general 'Regulatory Filings' (RNS) category as a corporate update, or potentially an Investor Presentation (IP) if the linked PDF is the presentation itself. Given the structure—a news announcement linking to a presentation PDF—and the lack of specific financial reporting headers, RNS is the most appropriate general regulatory announcement category, although IP is a close second if the focus was purely on investor material. However, RNS serves as the best catch-all for significant corporate news updates that aren't strictly financial results or management changes. The document length (9376 chars) is substantial enough that it is not just a brief 'Report Publication Announcement' (RPA).
2016-11-14 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.